Physician profile
Carrie Pascoe
NPI 1427010313
$2,316.31
in general payments reported to CMS, 2019-2025
28 companies · $825 in 2025
The $825 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $194 · 2022: $327 · 2023: $445 · 2024: $525 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,776 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,776.44 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $480.22 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $268.00 | 2022-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $264.52 | 2021-2025 | |
| Abbott Laboratories | $244.42 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $208.88 | 2021-2025 | |
| Amgen INC. | $91.57 | 2024-2025 | Evenity, Prolia, Repatha |
| Exact Sciences Corporation | $85.83 | 2024-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $80.54 | 2022-2024 | Breztri, Airsupra |
| Dynavax Technologies Corporation | $76.51 | 2022-2025 | Heplisav-B |
| Glaxosmithkline, LLC. | $72.74 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $62.72 | 2023-2024 | Rexulti |
| Astellas Pharma US INC | $57.92 | 2023-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $40.91 | 2021-2023 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $35.04 | 2022 | |
| Lundbeck LLC | $29.67 | 2024-2025 | Rexulti |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $22.75 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $20.34 | 2025 | |
| Neurelis, INC. | $19.92 | 2023 | Valtoco |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
| Idorsia Pharmaceuticals US INC | $18.02 | 2023 | Quviviq |
| Dexcom, INC. | $17.50 | 2025 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $16.47 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Esperion Therapeutics, INC. | $15.68 | 2025 | Nexletol |
| Currax Pharmaceuticals LLC | $15.51 | 2024 | Contrave |
| Philips North America LLC | $14.74 | 2024 | (5050) Extended Holter |
| Insulet Corporation | $13.59 | 2021 | |
| Amarin Pharma, INC. | $11.74 | 2021 | |
| Mylan Specialty L.P. | $11.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Pascoe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.